Samsung C&T's ownership structure for the common stock as of March 31, 2026 is as follows;
- Controlling shareholder and related parties 38%, Domestic institutions 14%, foreigners 30%, domestic individuals and others 18%
For further information, please refer to [IR > Stock Information > Ownership Structure].

As of March 31, 2026, total number of shares issued by Samsung C&T is 163,636,571 shares. Of the total volume, 162,168,981 shares are common stock and 1,467,590 shares are preferred stock.
※ For your information, the listing date of the new shares issued after the merger is September 15, 2015.

Stock related information can be found at [IR > Stock Information > Stock Charts] and [IR > Stock Information > Valuation]and .

Samsung C&T wholly owns Samsung Welstory—its food & beverage subsidiary—and holds approximately 43% of Samsung Biologics and approximately 43% of Samsung Epis Holdings, a bio investment holding company.
Samsung Epis Holdings wholly owns Samsung BioEpis, a biosimilar and new drug development company, and EPIS NexLab, a next-generation biotechnology company.

Generally, dividends are paid within 1 month after the BOD approves the financial statements, including the total dividend amount, at the annual general meeting of shareholders, to the registered shareholders as of the end of December, as stipulated in the relevant regulations.
At the annual general meeting of shareholders on March 20, 2026, the annual financial statements including the total dividend amount (KRW 2,800 per common share, KRW 2,850 per preferred share), were approved.
ㆍPeriod: July 24, 2015 – October 8, 2015
ㆍRepurchased shares: 2.5 million shares, KRW 409 billion

Samsung C&T's common and preferred stock is listed on Korea Exchange(KRX) under the ticker symbol of 028260, 02826K respectively.